Malvern, PA, United States of America

Ocugen, Inc.


USPTO Granted Patents = 7


Trademarks = 6

Forward Citations = 9

Loading Chart...
Loading Chart...

14 inventors (with patents filed for the assignee):

goldMedal Sandeep Jain (4 out of 9 patents)

silverMedal Shankar Musunuri (4 out of 4 patents)

bronzeMedal Uday Bhaskar Kompella (3 out of 7 patents)

4.  Robert Lane Smith (2 out of 19 patents)

5.  Hans P I Claesson (2 out of 9 patents)

6.  Laurence J B Tarrant (2 out of 21 patents)

7.  Rasappa Gounder Arumugham (1 out of 12 patents)

8.  Akihiko Kusanagi (1 out of 12 patents)

9.  Sonya Shortkroff (1 out of 10 patents)

10.  Eric J Roos (1 out of 9 patents)

11.  Arun K Upadhyay (1 out of 1 patent)

12.  Matthew Nudell (1 out of 1 patent)

13.  Gopalam Somasekhar (1 out of 1 patent)

14.  Eric Blahut (1 out of 2 patents)


7 patents:

Company Overview
Ocugen, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases. The company's pipeline includes gene therapies, biologics, and small molecules to treat retinal diseases like inherited retinal disorders and dry age-related macular degeneration. Ocugen is committed to improving the lives of patients with sight-threatening diseases through innovative treatments.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

7 Patents

#41 in Malvern, PA

#1,438 in Pennsylvania

#39,929 in US

Malvern, PA (US)
Malvern, PA, United States of America
Forward Citations = 9

14 inventors:

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Ocugen, Inc.. Retrieved from https://idiyas.com/company/ocugen

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…